Trends in the Use and Indications for Intracytoplasmic Sperm Injection Between 2005 and 2017: A State-Wide Descriptive Cohort Analysis

2005年至2017年胞浆内单精子注射的使用及适应症趋势:一项全州范围的描述性队列分析

阅读:1

Abstract

BACKGROUND: Intracytoplasmic sperm injection (ICSI) was first developed to overcome male factor infertility. ICSI has increased in uptake globally, including in cases where its use is non-essential for fertilisation. AIMS: To identify temporal trends in the use of, and indications for ICSI in an Australian context. MATERIALS AND METHODS: A statewide descriptive cohort study examining the trends in ICSI uptake and reported indication/s for ICSI use. The cohort included women undergoing IVF between 2005 and 2017 at IVF clinics across Victoria, Australia that resulted in a birth after 20 weeks' gestation. RESULTS: The dataset comprised 32 102 assisted reproduction cycles: 22 873 (71.3%) ICSI and 9229 (28.7%) conventional IVF. In 2005, ICSI accounted for 60.6% (1182/1952) of cycles, increasing to 79.5% (2344/2947) by 2017 (p(trend) < 0.001). Testicular sperm retrieval as an indication for ICSI remained consistent over time (p(trend) = 0.15). Male factor infertility as an indication decreased over time (p(trend) = 0.007). Vitrified oocyte thaw (p(trend) = 0.016) and 'unexplained subfertility' (p(trend) = 0.30) cycles did not surpass 1.7% (39/2293) and 0.4% (9/2048), respectively of total cycles in any year. Donor sperm (p(trend) = 0.001), pre-implantation genetic testing (p(trend) = 0.004), female factors associated with poor IVF outcome (p(trend) = 0.005) and advanced maternal age (p(trend) = 0.005) all increased as indications for ICSI over time. 'Unspecified' indication accounted for the majority of ICSI cycles after 2008 (p(trend) = 0.015). CONCLUSIONS: During our study period, the total use of ICSI increased by 18.9%. Notably, most of these cycles were not medically indicated.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。